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1. Introduction 
Lipoproteins are large lipid/protein complexes that play a major role in transport of lipids 
and lipophilic molecules in the plasma and central nervous system (CNS). Plasma 
lipoproteins represent a dynamic continuum of particles that are constantly undergoing re-
modulation in their lipid and protein components leading to re-structuring of the particle 
under normal physiological conditions. The re-modulation is the result of lipid transfer and 
metabolism mediated by non-enzymatic and enzymatic processes, and of lipid 
association/dissociation behavior of apolipoproteins. Variations in protein and lipid 
components and composition arise because of changes in the feeding, metabolic and 
hormonal states, and due to differences in age, gender and disease states. 
In this chapter, we will focus on oxidation of lipoproteins, paying attention to sources of 
oxidative stress, oxidation products of specific lipid and protein components, and the 
pathophysiology of oxidized lipoproteins in various disease states. The disease states that 
are addressed in this chapter include cardiovascular disease (CVD)/atherosclerosis, 
Alzheimer’s disease and diabetes. 
2. Lipoproteins 
2.1. Classes of lipoproteins in plasma and CNS 
Lipoproteins are classified based on their density, ranging from high density lipoproteins 
(HDL), low density lipoproteins (LDL), intermediate density lipoproteins (IDL), very low 
density lipoproteins (VLDL) and, chylomicrons (CM), Figure 1. They can also be classified 
based on their mobility during electrophoresis on an agarose gel as α-, pre-β- and β-
lipoproteins, which correspond to HDL, VLDL and LDL, respectively. Lipoproteins vary 
significantly in particle diameter and density, protein and lipid components and 
composition. In general, the particle diameter is inversely related to the density. 
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Figure 1. Lipoprotein classes. The classification of the major types of lipoproteins is based on their 
densities obtained by flotation ultracentrifugation analysis. The density range for each class is shown, in 
addition to the lipid (red) and protein (blue) content. The diagram is not to scale. 
One of the main functions of lipoproteins is to transport hydrophobic factors in the highly 
aqueous vascular system. The CM is composed of lipids of dietary origin and is synthesized 
by the intestines. The VLDL is synthesized and secreted by the liver, and plays a role in 
distribution of lipids synthesized by the liver to the peripheral tissues. In the blood stream, 
the VLDL undergoes particle re-modulation to IDL and LDL, during which process the LDL 
become enriched in cholesterylesters. LDL plays a predominant role in delivery of 
cholesterol to the peripheral tissues and to the liver, with the cell surface-localized LDL 
receptor (LDLr) family of proteins playing a role in the cellular uptake and internalization of 
lipoproteins in target cells. The HDL may be synthesized by the liver and intestines or 
derived from other lipoproteins. In addition, peripheral tissues such as the macrophages are 
an important source of HDL, which are formed from cellular cholesterol efflux, and 
eventually transported to the liver. This process is called reverse cholesterol transport 
(RCT), which is an important mechanism for removal of peripheral cholesterol to the liver 
for eventual disposal.  
Much less is known about lipoprotein metabolism in the CNS. Studies on lipoproteins 
secreted by astrocytes and those isolated from the cerebrospinal fluid (CSF) indicate the 
presence of only HDL-sized particles; large triglyceride-containing lipoprotein particles 
have not been detected in the CNS. The CNS maintains autonomy in terms of cholesterol 
synthesis and metabolism, right from the time when the blood brain barrier is established 
during development. One of the main functions of HDL secreted by astrocytes appears to be 
cholesterol delivery to the neurons via the LDLr family of proteins, for eventual use in the 
process of synaptogenesis. 
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2.2. Lipid and protein components of lipoproteins 
In general lipoproteins are spherical in shape with a monolayer of amphipathic lipids (for 
example phospholipids, cholesterol and sphingolipids) and proteins encircling a core of 
neutral lipids (such as triglycerides and cholesterylesters), Figure 2. The lipid composition 
and content vary significantly in the different lipoproteins: in general, the larger 
lipoproteins (CM, VLDL and IDL) are enriched in triglycerides, while the smaller 
lipoproteins (LDL and HDL) are enriched in cholesterylesters and cholesterol. Unesterified 
or free cholesterol is esterified to cholesterylester by the action of lecithin-cholesterol 
acyltransferase (LCAT) on HDL. The phospholipids serve as the donor of the fatty acyl 
chains (especially 18:1 or 18:2 fatty acids) utilized in the esterification process. The fatty acid 
composition of triglycerides in the fasted state is dominated by 16:0 and 18:1 fatty acids.  
 
Figure 2. Schematic representation of a generic lipoprotein particle. Lipoproteins have a spherical 
geometry with a monolayer of amphipathic lipids and proteins encircling a core of neutral lipids. ApoB-
100 (pale blue) is a single large polypeptide and is the non-exchangeable component of  lipoproteins 
such as VLDL and LDL. The molecular mass of exchangeable lipoproteins (yellow cylinders) varies 
from 8-50 kDa. The exchangeable apolipoproteins have the ability to exist in lipid-free and lipid-bound 
states. 
The protein composition and content of the lipoproteins also vary significantly from one 
particle to another. There are two types of apolipoproteins: non-exchangeable and 
exchangeable. The non-exchangeable apolipoproteins, apolipoprotein B-100 (apoB-100) and 
apoB-48, are present as a single copy per lipoprotein particle: apoB-100 on VLDL, IDL or 
LDL and apoB-48 on CM and CM remnants. ApoB-100 is 4536 residues long that is 
synthesized in the liver, while apoB-48, represents the N-terminal 48% of apoB-100, and is 
synthesized in the intestines. Both apoB-100 and apoB-48 are integral to the structure and 
stability of the lipoprotein particle. There are different types of exchangeable 
apolipoproteins, Table 1, which undergo a reversible association with lipoproteins 
depending on the metabolic state.  
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Apolipoprotein Lipoprotein Function
ApoAI HDL activates LCAT; promotes ABCA1-
mediated cholesterol efflux in RCT 
ApoAII HDL Inhibits LCAT 
ApoAIV Chylomicrons, HDL Activates LCAT, cholesterol clearance 
and transport 
ApoB-48 Chylomicron and chylomicron 
remnants 
Cholesterol clearance and transport; 
lacks LDLr binding sites 
ApoB-100 VLDL, IDL and LDL Binds to LDLr 
ApoCI VLDL, HDL Activates LCAT 
ApoCII VLDL, IDL, chylomicrons Activates lipoprotein lipase 
ApoCIII VLDL, IDL, chylomicrons Inhibits lipoprotein lipase 
ApoD HDL Carrier proteins family (lipocalins) 
ApoE2 VLDL, IDL, chylomicrons, 
chylomicron remnants 
Poor LDLr binding activity; 
associated with Type III 
hyperlipoproteinemia and CVD 
ApoE3 HDL, VLDL, IDL, chylomicron 
remnants (higher binding 
preference for HDL over VLDL) 
Binds to LDLr family of proteins with 
high affinity; significant role in 
cholesterol efflux and RCT in 
atherosclerosis  
ApoE4 VLDL, HDL, IDL, chylomicron 
remnants (higher binding 
preference for VLDL over HDL) 
Binds to LDLr family of proteins with 
high affinity; associated with CVD 
and Alzheimer’s disease 
ApoM HDL  Transports sphingosine-1-phosphate 
Apo(a) Lipoprotein(a) (Lp(a)) Linked to apoB-100 via disulfide 
bond; similar to plasminogen 
1 Adapted with permission from the AOCS Lipid Library, “Plasma Lipoproteins: Composition, Structure and 
Biochemistry,” Table 3, ‘The main properties of apoproteins, in http://lipidlibrary.aocs.org/lipids/lipoprot/index.htm, 
accessed June 12, 2012  
Table 1. Major apolipoprotein components of lipoproteins and associated functions1 
The exchangeable apolipoproteins have the ability to exist in lipid-free and lipid-bound 
states, and undergo a large conformational change upon transitioning from one state to the 
other. Exchangeable apolipoproteins are characterized by an abundance of amphipathic α-
helices that are folded into a helix bundle. For example, in the case of apoE, the protein is 
composed of a series of α-helices that are folded into an N-terminal (NT) and a C-terminal 
(CT) domain. The NT domain is comprised of a 4-helix bundle bearing the LDLr binding 
sites on helix 4, which has an abundance of basic residues, while the CT domain harbors 
high-affinity lipid binding sites and apoE self-association sites. A similar arrangement was 
noted for apoAI; however, apoAI does not have the capability to interact with LDLr. 
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In summary, lipoprotein particles offer several targets that are vulnerable to attack by 
oxidative species. Oxidative modification is expected to compromise the structure and 
function of the protein and lipid components.  
3. Oxidative stress 
Reactive oxygen species (ROS) generally refer to oxygen free radicals with one or more 
unpaired electrons, and other highly reactive oxygen-containing molecules. They may be 
generated by the cells as products of normal cellular metabolism, or derived from 
exogenous sources including environmental pollutants, which could in turn, trigger further 
release of ROS. Whereas the ROS may be beneficial at low concentrations and play key 
physiological roles, their deleterious effect at high concentrations contributes to the etiology of 
several disease states. Organisms have developed an exquisite arsenal of defense mechanisms 
to combat the harmful effects of ROS, thereby maintaining a redox homeostasis. However, 
when the ROS overcome the cellular defense mechanism, there is a dysregulation of the redox 
balance, which leads to the state of oxidative stress (Esterbauer et al., 1991).  
3.1. ROS 
The high reactivity of free radicals is attributed to the unpaired electron(s) on the oxygen 
molecule. The primary ROS is the superoxide anion, which is generated by the addition of 
one electron to molecular oxygen during mitochondrial electron transport (Equation 1).  
This in turn gives rise to hydrogen peroxide following the action of antioxidant enzymes, 
superoxide dismutases (SOD) (Equation 2). The superoxide anions also give rise to the 
hydroxyl radicals in the presence of trace amounts of Fe2+ (Fenton reaction) (Equation 3); the 
hydroxyl radical is an extremely deleterious species that is capable of causing indiscriminate 
damage in the immediate vicinity of its formation. 
 2 2O e O Superoxideanion
    (1) 
 SOD2 2 2 2O 2H H O +O Hydrogen peroxide
     (2) 
 
2 -
2 2 2 2O H OH+OH +O Hydroxyl radical
FeO
    (3) 
SOD catalyzes the dismutation of superoxide anion into oxygen and hydrogen peroxide, 
thereby affording protection to the cell. Three forms of SOD exist in humans and other 
mammals: SOD1 is located in the cytoplasm, SOD2 in the mitochondria, while SOD3 is 
extracellular. Mutations in SOD lead to diseases commonly associated with high oxidative 
stress such as familial amyotrophic lateral sclerosis, Parkinson’s Disease, and cardiovascular 
disease (Fukai et al., 2002; Noor et al., 2002; Tórsdóttir et al., 2006). Overexpression of SOD 
inhibits LDL oxidation by endothelial cells (Fang et al., 1998). Higher SOD levels were 
demonstrated to be protective against LDL oxidation in vitro (Laukkanen et al., 2000). 
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Red blood cells (RBC) are particularly susceptible to ROS and free radical stress due to its 
constant interactions with oxygen. Despite their lack of mitochondria, RBC are under 
tremendous oxidative stress, due to the abundance of hemoglobin. Hemoglobin is prone to 
oxidation through either exogenous or endogenous sources, which results in superoxide 
production. Therefore, the RBC contains many SOD enzymes to convert the superoxides to 
hydrogen peroxide. Furthermore, hydrogen peroxide can combine with hemoglobin to form 
ferrylhemoglobin, a strong oxidizing agent (Rifkind et al, 2002). The RBCs are also equipped 
with other antioxidant enzymes such as catalase and glutathione peroxidase to overcome 
the harmful effects of ROS. 
3.2. Reactive aldehydes 
It is well established that polyunsaturated fatty acids (PUFA) undergo lipid peroxidation 
that is initiated by ROS, which generate a ‘spectrum’ of reactive aldehyde species. The 
reactive aldehydes formed in biological systems are more complex than those formed in 
simple systems like purified lipid preparations and their physiological concentrations are 
believed to be lower. They play a crucial role in amplifying the free radical-initiated reaction 
by generating a complex array of toxic end products. Although considered as end products 
of oxidative damage of lipids, the aldehydic products display reactivity with a wide variety 
of biological molecules under cellular conditions, thereby enhancing the pathogenesis of the 
diseases. They are therefore considered as toxic second messengers of oxidative stress and 
lipid peroxidation. Protein-bound aldehydes have been proposed as potential markers of 
oxidative stress as evidenced by immunohistochemical analysis of atherosclerotic lesions 
(Uchida et al., 1998a). Numerous α,β-unsaturated aldehydes have been reported in 
literature: we will focus on acrolein, 4-hydroxynonenal (4-HNE) and malondialdehyde 
(MDA), Figure 3.  
 
Figure 3. Major aldehydic products of lipid peroxidation 
3.2.1. Acrolein 
Acrolein is an acrid smelling environmental pollutant that is formed during combustion of 
organic and plastic substances (Beauchamp et al., 1985). It is present as one of the major 
components in the gaseous phase of tobacco smoke (up to 140 μg/cigarette) (Witz, 1989).  It 
is also generated as a natural metabolite during oxidative stress mediated lipid peroxidation 
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(Uchida et al., 1998b). In addition, oxidation of threonines by myeloperoxidase (MPO) gives 
rise to acrolein (Anderson, et al., 1997; Savenkova et al., 1994). Acrolein is the most reactive 
of all α,β-unsaturated aldehydes; it causes oxidative modification of proteins by reacting 
with the sulfhydryls of cysteines, ε-amino groups of lysines and imidazole group of 
histidines (Witz, 1989; Esterbauer et al., 1991). Some possible products formed upon reaction 
of acrolein with lysine side chains include aldimine adducts (Schiff base formation), 
propanal adducts (Michel addition) and Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-
lysine), Figure 4. 
3.2.2. 4-HNE 
Discovered more than 50 years ago, alkenals have been under intense scrutiny in terms of 
their chemistry, biochemistry, toxicology and as oxidative stress agents. Amongst these 
alkenals, 4-HNE was determined to be the most toxic. It was discovered to be a product of 
lipid peroxidation, particularly of n-6 PUFA such as linoleic acid and arachidonic acid. Since 
then, 4-HNE has been implicated in a number of diseases, including atherosclerosis, 
Alzheimer’s Disease, Parkinson’s Disease, liver cirrhosis, and cancer (Zarkovic, 2003).  
 
Figure 4. Modifications of lysine side chains by acrolein. The major lysine modification products of 
acrolein are shown, along with the expected increments in molecular weight during mass spectral 
analysis. Adapted from Furuhata et al, 2003.  
From a chemical perspective, the reactivity of 4-HNE is conferred by the carbonyl group at 
C1 position, and a C=C bond between the second and third carbons which provide a partial 
positive charge to C3 (Schaur, 2003). This results in 4-HNE being highly reactive towards 
thiol and amino groups of proteins. 4-HNE reacts with thiols via a Michael addition, in 
which a nucleophile such as the sulfhydryl of cysteine or glutathione reacts with the C3 of 
HNE to form a covalent adduct. In addition, amino compounds such as lysine, 
ethanolamine, guanine, and the imidazole group of histidine are capable of forming Michael 
addition adducts with 4-HNE. 4-HNE can also undergo reactions involving a reduction or 
an epoxidation of the double bond. 4-HNE has been shown to react in vivo with common 
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biomolecules, and can often have an inhibitory role with enzymes (Schaur, 2003; 
Korotchkina et al, 2001). Cross-reactivity of anti-4-HNE antibody with oxidized LDL (Ox-
LDL) suggests that 4-HNE may contribute to the overall process of atherosclerotic plaque 
formation (Uchida et al., 1993).  
3.2.3. MDA 
In fresh samples, MDA is formed mainly from PUFA such as arachidonic acid (Esterbauer et 
al., 1991). Initially determined by the thiobarbituric acid (TBA) assay as TBA reactive 
substances (TBARS), the presence of pre-existing MDA or protein-bound MDA needs to be 
confirmed by other sensitive assays as well. Under physiological conditions, MDA readily 
modifies protein side chains forming stable cross-linked adducts with the ε-amino groups of 
lysines.  Other side chains that may be modified include those of histidine, tyrosine, arginine 
and methionine. 
While the levels of acrolein, 4-HNE, MDA and other aldehydic compounds per se are 
thought to be too low for detection, their role in mediating oxidative damage has been 
confirmed by the presence of autoantibodies against aldehyde-modified proteins. It 
provides evidence for the in vivo occurrence of lipid peroxidation products and their role in 
disease progression (Steinberg et al, 1989). We have a better understanding of the association 
between lipid peroxidative products, oxidative stress and disease progression, in part due to 
the development of antibodies directed against oxidized lipids and protein-bound aldehydes 
in the past two decades, Table 2. Currently, we have a repertoire of antibodies directed against 
different types of oxidatively modified lipids and proteins, Table 2, that serve as powerful 
tools for ELISA, immunohistochemical and immunoblotting analyses. 
3.3. Sources of ROS 
In addition to the mitochondrial electron transport, there are enzymatic sources of ROS that 
contribute to the redox status in biological systems. Located in the blood stream, they are of 
relevance to lipoprotein oxidation. 
3.3.1. MPO 
MPO is an enzyme found abundantly in neutrophil granulocytes and to some extent in 
macrophages. It is a lysosomal protein stored in the azurophilic granules in neutrophils and 
can be identified by its characteristic green heme pigment. During the respiratory burst of 
the neutrophil, MPO catalyses the production of hypochlorous acid (HOCl) from hydrogen 
peroxide and chloride anion (Equation 4). MPO is also responsible for generation of 3-
chlorotyrosine and 3-nitrotyrosine; individuals with coronary artery disease show elevated 
levels of these two products in their blood and HDL. MPO has been shown to play a role in 
promoting atherosclerotic lesions through oxidative modification of apoAI (Shao et al., 2012) 
(described under apoAI).  
 - +2 2 2H O +Cl +H HOCl+H O  (4) 
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Lipid peroxidation products mAb Epitope 
Oxidized lipids   
a9-Hydroxy-10E,12Z-octadecadienoic acid (9-HODE) 9H2 9-HODE 
b13-Hydroxy-9Z,11E-octadecadienoic acid (13-HODE) 13H1 13-HODE 
a12-Hydroxyeicosatetraenoic aci (12-HETE) 12H8 12-HETE 
aLeukotoxin (epoxylinoleic acid) 21D1 Leukotoxin 
a7-Ketocholesterol (7-KC) 35A-8 7-KC 
c15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) 11G2 15d-PGJ2 
Protein-bound aldehydes   
dAcrolein (ACR) 5F6 ACR-lysine 
eCrotonaldehyde (CRA) 82D3 CRA-lysine 
a2-Hexenal (HE) CT5 HE-lysine 
f2-Nonenal (NE) 27Q4 NE-lysine 
gMalondialdehyde (MDA) 1F83 MDA-lysine 
h4-Hydroxy-2-hexenal (HHE)  53 HHE-histidine 
i2-Hydroxyheptanal (2HH) 3C8 2-HH-lysine 
j4-Hydroxy-2-nonenal (HNE) HNEJ2 HNE-histidine 
k4-Hydroxy-2-nonenal (HNE) 2C12 HNE-lysine 
l4R-4-Hydroxy-2-nonenal ((R)-HNE) R310  (R)-HNE-histidine 
m4S-4-Hydroxy-2-nonenal ((S)-HNE) S412 (S)-HNE-histidine 
n4-Hydroperoxy-2-nonenal (HPNE) PM9 HPNE-lysine 
o4-Oxo-2-nonenal (ONE)  9K3 ONE-lysine 
Protein-bound core aldehyde   
p9-Oxononanoylcholesterol (9-ONC) 2A81  9-ONC-lysine 
aUnpublished 
bShibata et al. (2009) Acta Histochem. Cytochem. 42, 197; cShibata et al. (2011) JBC 277, 10459; dUchida et al. (1998) 
PNAS 95, 4882; eIchihashi et al. (2002) JBC 276, 23903; fIshino et al. (2010) JBC 285, 15302; gYamada et al. (2001) JLR 42, 
1187; hYamada et al. (2004) JLR 45, 626; iItakura et al. (2003) BBRC 308, 452; jToyokuni et al. (1995) FEBS Lett. 359, 189; 
kItakura et al. (2000) FEBS Lett. 473, 249; lHashimoto et al. (2003) JBC 278, 5044; mHashimoto et al. (1995) JBC 278, 5044; 
nShimozu et al. (2011) JBC 286, 29313; oShibata et al. (2011) JBC 286, 19943; pKawai et al. (2003) JBC 278, 21040; qKawai et 
al. (2003) JBC 278, 50346 
Table 2. Lipid peroxidation-specific monoclonal antibodies 
3.3.2. NADPH oxidase 
NADPH oxidase is an enzyme complex that is normally found in the plasma membranes of 
neutrophils and monocytes. Like MPO, it is activated during the respiratory burst of the 
neutrophil. Its main role is to generate superoxide by transferring electrons from NADPH to 
molecular oxygen (Equation 5). The superoxide is then used to destroy phagocytosed 
bacteria or pathogens. NADPH oxidase and its product, superoxide, are major contributory 
factors for foam cell formation in atherosclerosis (Meyer & Schmitt, 2000). 
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 - + +2 22O +NADPH 2 O +NADP +H   (5) 
3.3.3. Lipoxygenase 
Lipoxygenases are iron-containing enzymes that catalyze the dioxygenation of PUFA in 
lipids. Specifically, they form hydroperoxides from fatty acids and molecular oxygen. 15-
lipoxygenase is the main protein in this family; it is involved in the metabolism of 
eicosanoids (prostaglandins, leukotrienes), which function as secondary messengers. 15-
lipoxygenase has been shown to be involved in LDL oxidation (Bailey et al., 1995), with 
considerably greater 15-lipoxygenase activities in atherosclerotic compared to normal aortas 
(Hiltunen et al., 1995).  
4. Lipoprotein oxidation  
We now turn to the specifics of lipoprotein oxidation with reference to the different lipid 
and protein components. 
4.1. Oxidation of lipid components 
Of the different lipid components that may be potentially oxidized in various lipoprotein 
particles, we will focus on the oxidation of fatty acyl chains, including those on 
phospholipids, cholesterylester and triglycerides, and on cholesterol derivatives. The reader 
is referred to a comprehensive review by Subbaiah and colleagues (Levitan et al., 2010) for 
an introduction to the role of ceramides in Ox-LDL and of sphingosine 1-phosphate in HDL 
4.1.1. Oxidation of fatty acyl chain 
One group of biological targets that are highly vulnerable to attack by ROS and aldehydes 
are the lipids: their abundance in lipoproteins and the ease with which their unsaturated 
bonds are oxidatively modified make them susceptible to damage. Products of lipid 
peroxidation have been associated with the pathophysiology of numerous disease states, 
including atherosclerosis, diabetes and cancer. Although found in low concentrations in 
normal healthy tissues, they are found to be enriched in pathological cells and tissues, 
including macrophage foam cells and atherosclerotic lesions (Olkkonnen, 2008; Brown & 
Jessup, 1999; Olkkonen & Lehto, 2004; Javitt, 2008; Tsimikas et al., 2005; Berliner & Watson, 
2005). PUFA peroxidation products cause further damage to proteins by oxidative 
modification of amino acid side chains and formation of protein carbonyl groups (Refsgaard 
et al., 2000). 
Briefly, lipid peroxidation is initiated by the hydroxyl radical abstracting a hydrogen from 
the methylene group adjacent to a double bond of fatty acids, Figure 5. The fatty acid may 
also be part of the phospholipid at the sn-2 position or esterified to the –OH group of 
cholesterol in a lipoprotein. This process gives rise to an unstable lipid radical, which 
undergoes rearrangement of double bonds and addition of oxygen to form a peroxyl radical. 
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The lipid radical or the peroxyl radical could react with a neighbouring fatty acyl chain as 
well, thereby propagating the peroxidation process. The chain reaction may be terminated 
by eventual formation of a lipid hydroperoxide.  
 
Figure 5. Lipid peroxidation. The lipid peroxidation process may be divided into the initiation, 
propagation and termination steps; only the double bond containing segment of a fatty acid is shown. 
In the context of a lipoprotein, it was postulated that LDL oxidation was initiated through cell-
generated ROS formation, with the involvement of the lipoxygenase pathway (Cyrus et al, 
1999). Both apoE-null and LDLr-null mice genetically deficient in the 12/15-lipoxygenase were 
found to have significantly less atherosclerosis. Other groups developed mice overexpressing 
the 12/15-lipoxygenase, and found spontaneous aortic fatty streak lesions on a chow diet 
(Reilly et al., 2004). Finally, it was shown that the endothelial cells within the vessels required 
12/15-lipoxygenase to generate oxidized phospholipids. It was also shown that the MPO 
pathway contributed to Ox-LDL in human atherosclerotic lesions (Savenkova et al., 1994).  
LDL oxidation may occur within the arterial endothelial cells, which have high levels of 
precursor molecules like linoleic acid and arachidonic acid - fatty acids that are involved in 
producing eicosanoids. Hydroperoxide reaction with linoleic acid produces 13(S)-
hydroperoxy-octadecadienoic acid (13(S)-HPODE), and reaction with arachidonic acid 
produces 15(S)-hydroperoxy-eicosatetraenoic acid (15(S)-HPETE). These molecules are 
present as part of LDL surface phospholipids and trigger further oxidation of phospholipids 
with arachidonic acid. These are early events occurring prior to apoB-100 modification and 
constitute the ‘minimally-modified’ LDL (Navab et al., 2001). Another consequence of 
phospholipid oxidation is fragmentation of the fatty acyl group at sn-2 position resulting in 
short chain fatty acids, which structurally and functionally resemble platelet activating 
factors with chemotactic activity.  
Although less understood, in vitro oxidation of HDL is also shown to generate oxidized 
lipids and proteins. It is likely that HDL lipids may be oxidized initially even before LDL 
lipids, upon exposure of human plasma to peroxyl radicals, Cu2+ ions or lipoxygenase 
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(Garner et al., 1998). These studies also show that Met residues are oxidized in apoAI and 
apoAII. Further, 1H and 31P NMR analysis indicate a loss of the unsaturated system with 
appearance of epoxides on fatty acyl chains and 5,6-epoxide derivatives of cholesterol 
indicating significant modification of HDL (Bradamante et al., 1992). 
4.1.2. Oxysterols 
Oxysterols are molecules that are formed from the oxidation of cholesterol, which can occur 
at several sites (Vaya & Schipper, 2007). They display higher water solubility compared to 
cholesterol. The major oxysterols isolated from plasma LDL include 7α-OH and 7β-OH 
cholesterol. In addition, 7-keto cholesterol, which impairs cholesterol efflux and reduces cell 
membrane fluidity, and 5,6-epoxide derivatives of cholesterol, have also been identified in 
Ox-LDL (Levitan et al., 2010). Other types of oxysterols have been localized in 
atherosclerotic lesions, including those wherein the side chains of cholesterol are oxidized 
(for example, 27-hydroxycholesterol). The cytochrome P-450 system is largely responsible 
for generating the hydroxylated derivatives. They also function as transcriptional effectors 
and attenuate the Liver X Receptor (LXR). A majority of PUFA in LDL is esterified as 
cholesterylester; thus, hydroperoxide and hydroxide derivatives of cholesterylester are 
found in abundance in human atherosclerotic lesions. 
In the CNS, the neurons convert cholesterol to 24S-hydroxycholesterol (also known as 
cerebrosterol), Figure 6; the conversion facilitates its movement out of the CNS, since 
cholesterol as such does not cross the blood brain barrier. Almost all circulating 24S-
hydroxycholesterol originates from the brain (Lutjohann et al., 1996; Lutjohann et al., 2000; 
Bjorkhem et al., 1998) and may reflect CNS cholesterol turnover.  
 
Figure 6. 24S-hydroxycholesterol (obtained from: http://pubchem.ncbi.nlm.nih.gov) 
4.2. Oxidation of protein components 
4.2.1. ApoB-100 
From a historical perspective, apoB-100 was the earliest apolipoprotein to be identified as 
being a target for oxidative modification on lipoproteins (Steinberg et al., 1989). It is implied 
in the discussions involving Ox-LDL hypothesis, along with oxidation of the lipid moieties 
in LDL. The term Ox-LDL is used to identify LDL that has been modified to an extent that it 
is not recognized by the LDLr anymore; instead it becomes a ligand for the scavenger 
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receptors family of proteins. On the other hand, the term ‘minimally-modified’ LDL has 
been adopted to encompass the different preparations that have been modified enough to be 
chemically distinguishable from, but recapitulates the LDLr binding feature of, unmodified 
LDL. ApoB-100 is one of the oxidizable targets on lipoproteins: one of the earliest in vitro 
studies demonstrate that incubation of human LDL with 4-HNE (Haberland et al., 1984; 
Jurgens et al., 1986), results in modification of 45 lysines, 7 histidines, 23 serines and 51 
tyrosine residues on apoB-100. 
4-HNE forms covalent adducts with lysine residues on apoB-100, thereby blocking its ability 
to recognize the macrophage LDLr. Evidence for in vivo LDL oxidation was provided by 
immunocytochemical staining and immunoblot analysis of extracts from atherosclerotic 
lesions of LDLr-deficient rabbits using antibodies against Ox-LDL, MDA-lysine or 4-HNE-
lysine, (Palinski et al., 1990). This study also demonstrated higher titers of autoantibodies 
against MDA-conjugated LDL in the human and rabbit antisera. 4-HNE-modified LDL is an 
efficient ligand for scavenger receptors (Hoff & O’Neil, et al, 1993; Rosenfeld et al., 1990).  
ApoB-100 can also be modified by MPO, which leads to formation of chlorotyrosine and 
nitrotyrosine derivatives.  
4.2.2. ApoE 
ApoE is a 299 residue, 34 kDa protein that is commonly associated with VLDL, CM 
remnants and a sub-class of HDL. It is a major cholesterol transport protein in the plasma 
and the CNS (Hatters et al., 2006). In humans, apoE is polymorphic; variation in the APOE 
gene results in three major alleles, ε2, ε3 and ε4, occurring at frequencies of 8%, 77% and 
15%, respectively in the population. The products of the three alleles are the isoforms, 
apoE2, apoE3 and apoE4, which differ in the amino acids at positions 112 and 158: apoE2 
has Cys while apoE4 has Arg at these locations; apoE3 has a Cys and Arg at these locations, 
respectively. ApoE3 is considered an anti-atherogenic protein; individuals homozygous for 
the APOE ε2 allele are prone to developing familial type III hyperlipoproteinemia and 
premature atherosclerosis. The inheritance of one or more of the APOE ε4 alleles 
predisposes the bearer to hypercholesterolemia, as well as Alzheimer’s disease, affecting 
both the age of onset and the severity of these diseases. 
In vitro oxidative modification of the receptor-binding domain of apoE3 by acrolein generates 
epitopes recognized by an antibody specific for acrolein-lysine adducts, mAb5F6 (Tamamizu-
Kato et al., 2007) with formation of both intra- and inter-molecular cross-linked products. This 
modification resulted in severe impairment of three major functions of apoE3: (i) its ability to 
interact with the LDLr, a function mediated by specific lysines and arginines located on helix 4 
of the receptor-binding domain; (ii) its ability to bind heparin, which is facilitated 
predominantly by two specific lysines (K143 and K146), Figure 7; (iii) its ability to bind lipids. 
These studies indicate that acrolein either directly modifies the lysines in helix 4 that are 
involved in LDLr and heparin binding or that modification of lysines elsewhere on apoE3 
alters the conformation of lysines in helix 4, thereby disrupting its binding. Further evidence 
was provided by direct exposure of VLDL isolated from human plasma to acrolein or Cu2+, 
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which disrupted its ability to bind and internalize the lipoprotein particle via LDLr, LDLr-
related protein or HSPG on hepatocytes. (Arai et al., 1999; 2005). Taken together, oxidative 
modification appears to compromise the functional integrity of apoE3. 
 
Figure 7. Lysines relevant in LDLr and HSPG binding function of apoE3.  Ribbon diagram of 
apoE3 receptor-binding domain is shown with the LDLr- and HSPG-binding sites 
represented in green and yellow, respectively. 
From a physiological perspective, the loss of apoE function by oxidative modification has 
direct implications in CVD: (i) decreased uptake and internalization of apoE-containing 
lipoproteins leading to their accumulation in the blood; (ii) decreased ability of apoE to interact 
with heparan sulfate proteoglycans (HSPG) lining the blood vessels and cell surfaces, where 
apoE is believed to be stored; and (iii) impaired ability of apoE to interact with lipoproteins, 
which is an essential prerequisite for the receptor-binding domain to elicit LDLr binding.   
In the CNS, where apoE is the predominant apolipoprotein that has been identified so far, 
oxidative modification is expected to have serious implications in progression of 
neurological diseases such as Alzheimer’s disease in an isoform-specific manner. About 65% 
of individuals with late-onset familial and sporadic Alzheimer’s disease bear the APOE ε4 
allele (Huang et al., 2004). The precise mechanism by which apoE4 is associated with 
Alzheimer’s disease remains a contentious issue. While the role of apoE4 in aggravating the 
beta amyloid toxicity has received widespread attention, the inherent propensity of apoE4 to 
misfold noted under in vitro physiological conditions requires further scrutiny in vivo. 
Further, since oxidative damage plays a significant role in the pathogenesis associated with 
Alzheimer’s disease (Perry et al., 2002), it is likely that oxidative modification of apoE4 
further exacerbates its role in the etiology of the disease. Indeed, cerebrospinal fluid 
obtained by lumbar puncture in a limited number of Alzheimer’s disease patients 
homozygous for APOE3 or APOE4, and age-matched controls with or without dementia 
display a 50 kDa apoE-immunoreactive protein co-migrating with proteins immunoreactive 
for 4-HNE and MDA adducts (Montine et al., 1996; Bassett et al., 1999).  
A similar 50 kDa apoE-immunoreactive protein was also reported in P19 neuroglial cultures 
differentiated into neurons and astrocytes subjected to oxidative stress. Interestingly, apoE3 
appeared to be cross-linked to a greater extent than apoE4. The cross-linking has been 
attributed to the susceptible site provided by apoE3 in the form of Cys112, and the known 
reactivity of 4-HNE with sulfhydryl groups (Esterbauer et al., 1991). In vitro modification of 
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apoE3 or apoE4 (isolated from plasma) by 4-HNE yielded cross-linked products with apparent 
molecular weights corresponding to dimeric and trimeric apoE (Montine et al., 1996). A similar 
trend was noted with MDA. It is possible that the greater susceptibility of apoE3 to cross-
linking and oxidation than apoE4 is a reflection of its greater potency as an antioxidant. 
4.2.3. ApoAI 
ApoAI is a 243 residue, 28 kDa exchangeable apolipoprotein that is a major component of 
HDL.  Like apoE, it is composed predominantly of amphipathic α-helices, with an N-
terminal domain 4-helix bundle. Under normal physiological conditions, apoAI plays a 
critical role in promoting ATP Binding Cassette Transporter A1 (ABCA1)-mediated 
cholesterol efflux from macrophages. This aids in mobilizing cholesterol and phospholipids 
from peripheral tissues to the liver by the RCT process, for eventual disposal by biliary 
secretion. In atherosclerotic lesions, apoE plays a dominant role in RCT by virtue of the fact 
that cholesterol-laden macrophages secrete lipid-poor apoE, which in turn in promotes 
ABCA1-mediated cholesterol efflux (Huang et al, 1995). 
With both apoAI and apoE, a nascent discoidal form of HDL is generated that is composed 
of a bilayer of phospholipids and cholesterol circumscribed by the α-helices of the protein. 
The discoidal HDL is an excellent substrate for LCAT, the enzyme that catalyzes the transfer 
of a fatty acyl chain from phospholipids to the free hydroxyl group of cholesterol to form 
cholesterylesters. The conversion of the amphipathic free cholesterol to the hydrophobic 
cholesterylesters promotes its transition to the core of the lipoprotein particle, thereby 
generating a spherical HDL containing a cholesterylester core. The HDL is targeted to the 
liver and steroidogenic tissues where they are recognized by the scavenger receptor class B 
Type 1 (SR-B1), which mediate selective uptake of cholesterylesters into the cells.  
 
Figure 8. Immunohistochemical co-localization of apoAI and acrolein adducts in human atherosclerotic 
lesions. This research was originally published in The Journal of Biological Chemistry. Shao, B., Fu, X., 
McDonald, T. O., Green, P. S., Uchida, K., O’Brien, K. D., Oram, J. F. & Heinecke, J. W. Acrolein impairs 
ATP Binding Cassette Transporter A1-dependent cholesterol export from cells through site-specific 
modification of apolipoprotein A-I. J. Biol. Chem. (2005) Vol. 280, No. 43, pp. 36386-36396 © the 
American Society for Biochemistry and Molecular Biology. 
There is strong evidence that MPO oxidizes HDL in vivo (Daugherty et al., 1994; Bergt et al., 
2004; Pennathur et al., 2004; Zheng et al., 2004). In addition, aldehyde modification of HDL 
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is also associated with the loss in ability of HDL to activate LCAT (McCall et al., 1995). 
Acrolein modifies apoAI specifically at Lys226 in helix 10 converting it to Nε-(3-
methylpyridinium)lysine (MP-Lys). A corresponding decrease in ABCA1-mediated 
cholesterol efflux was also noted. In addition, immunohistochemical analysis demonstrated 
co-localization of acrolein-adducts and apoAI in human atherosclerotic lesions, Figure 8, 
confirming previous studies (Uchida et al., 1998b). Further chlorination of Tyr192 and 
oxidation of specific Met residues in apoAI via the MPO pathway impairs its ability to 
promote cholesterol efflux (Shao et al., 2010). Taken together, it appears that oxidative 
modification of HDL apoAI may be one of the contributory factors to atherogenesis. 
Figure 9 provides a simplified overview of the roles of apoB-100, apoAI and apoE in lipid 
distribution between liver and peripheral tissues. It also shows potential functional sites that 
are likely to be affected because of oxidative modification of lipoproteins. 
  
Figure 9. Distribution cholesterol mediated by apoB-100, apoE and apoAI. The green block arrow 
shows the general direction of the RCT process. The red stars draw attention to processes that are 
affected by oxidative modification of protein and lipid components of lipoproteins. 
5. Lipoprotein oxidation and disease states 
5.1. Atherosclerosis 
Atherosclerosis is one of the leading causes of death worldwide, and is commonly 
associated with coronary and cerebrovascular diseases (Rocha & Libby, 2009; Moore & 
Tabas, 2011). Originally considered purely a lipid-storage disease, it is now recognized that 
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atherosclerosis is intrinsically linked to inflammation, particularly with respect to 
involvement of innate and adaptive immunity.  
Atherosclerosis is a progressive disorder marked by several stages with varying extent of 
lesions marking each stage. It is initiated by accumulation of lipoproteins in the sub-
endothelium, typically at arterial branch points, which tend to have impaired laminar flow. 
The physiological response to this retention includes: (i) chemical modification (due to the 
production of ROS and other oxidative factors from intimal macrophages) and aggregation 
of the lipoproteins, (ii) early inflammatory response such as T cell recruitment, (iii) cytokine 
secretion, and, (iv) endothelial alterations. In response to the chemokines, the circulating 
monocytes enter the arterial wall and eventually differentiate to macrophages under the 
influence of macrophage colony stimulating factors. 
The macrophages internalize oxidized and modified lipoproteins via several types of 
scavenger receptors, including class A and B scavenger receptors (e.g. CD36) and lectin-like 
oxidized LDLr-1 (LOX-1). Mice lacking CD36, platelet-activating-factor receptor, and toll-
like receptors 2 and 4 show decreased atherosclerosis. The internalized cholesterol is stored 
in the cytoplasm as cholesterylester lipid droplets, surrounded by a monolayer of 
phospholipids. When viewed by electron microscopy, these cells have a foamy appearance, 
and are therefore called foam cells. Foam cell formation marks the earliest pathological 
lesion in atherosclerosis called ‘fatty streaks’. 
As the fatty streaks progress, they induce migration of smooth muscle cells from media to 
the intima of the arterial wall, which is accompanied by secretion of collagen and matrix 
proteins and macrophage proliferation. As lipid accumulation continues to occur in 
macrophages, smooth muscle cells also take up lipids. Collectively, these processes give rise 
to fibrous lesions. As the lesion progresses, foam cells die and release lipids, which 
aggregate with lipoproteins trapped in the matrix, eventually leading to advanced lesions 
with calcification and hemorrhage. 
Ox-LDL also plays a role in modulating smooth muscle function, by increasing their 
adhesion to macrophages and foam cells in the plaques. At low concentrations, Ox-LDL 
stimulates proliferation of smooth muscle cells, whereas at higher concentrations, they cause 
smooth muscle apoptosis by up-regulating levels of the pro-apoptotic lipid ceramide. 
During this process, a necrotic core is formed in the vessel lumen. The necrotic plaque is 
unstable and subject to disintegration or rupture, leading to formation of a thrombus. Ox-
LDL are key stimulators of the coagulation pathway, and promote the secretion of tissue 
factor from endothelial cells, which is required to form a clot. At various stages of the lesions 
unstable angina, heart attack or stroke may occur.  
In summary, our understanding of the atherogenesis process has progressed rapidly since 
the deleterious nature of Ox-LDL was first pointed out about 3 decades back. We now 
recognize it as a multifactorial disease with inflammation and oxidative stress playing key 
roles. The last decade has seen the additional role of HDL in mitigating the severity of 
atherosclerosis; in this context, the role of HDL (not HDL levels per se, but the robustness of 
HDL function) is currently under intense scrutiny.   
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5.2. Alzheimer’s disease 
Alzheimer’s disease is a neurodegenerative disorder that is clinically characterized by 
progressive cognitive decline and dementia. The major neuropathological hallmarks of this 
age-related disease are the extra cellular accumulation of amyloid beta peptide (Aβ), the 
intracellular presence of neurofibrillary tangles composed of hyperphosphorylated tau and 
the loss of cholinergic neurons in the brain. 
Several hypotheses have been put forward to explain the pathogenesis of Alzheimer’s 
disease, of which the oxidative stress hypothesis is of relevance here. In general, the brain of 
Alzheimer’s disease subjects is believed to be in a heightened state of oxidative stress and is 
characterized by higher levels of lipid peroxidation products (acrolein, 4-HNE and MDA) 
(Arlt et al., 2002; Butterfield et al., 2010). The brain is particularly susceptible to oxidative 
stress due to the high oxygen and metal content, lipid levels, and paucity of antioxidants 
(such as vitamins C and E) compared to normal tissues (Schippling et al., 2000). The 
Alzheimer’s disease brain is also rich in isoprostanes (a stable marker of peroxidation of 
arachidonic acid) and neuroprostanes (Lovell et al., 2001).  
Accumulation of soluble and insoluble assemblies of Aβ (a peptide composed of 39-43 
residues) in the brain parenchyma and in the cerebral vasculature is considered the primary 
event in Alzheimer’s disease pathogenesis by the amyloid hypothesis. Aβ is derived from 
the ubiquitously expressed transmembrane protein amyloid precursor protein by regulated 
intramembranous proteolysis. The oligomeric form of Aβ is considered as the most toxic 
species; one of the reasons for its toxicity is its ability to act as an oxidative stress agent in a 
lipid environment. The oxidative nature of Aβ has been attributed to the presence of Met35, 
which is capable of undergoing one-electron oxidation to form a sulfuranyl radical cation 
(S+). This in turn is able to abstract a H-atom from a fatty acyl chain as shown in Figure 7, 
and initiate a series of free radical-mediated events in a lipid milieu such as a membrane 
bilayer or a lipoprotein particle (Butterfield et al., 2005). 
In the CNS, apoE is localized on HDL-sized spherical and discoidal particles. Lipoproteins 
isolated from CSF of Alzheimer’s disease patients were shown to have a higher sensitivity to 
in vitro oxidation compared to those from normal subjects. It has also been shown that CSF 
lipoproteins can be oxidized through transition metal ions such as Cu2+ or Fe3+. These metal 
ions are present in CSF as complexes with metal-binding proteins like ceruloplasmin or 
transferrin (Schippling et al., 2000); under pathological conditions, they are released in a 
catalytically active form. Furthermore, Aβ itself can induce oxidation through interactions 
with metal ions. Aβ contains three histidines and one tyrosine, all of which can chelate 
transition metal ions. This promotes Aβ aggregation and a pro-oxidative state of Aβ through 
reduction of the transition metal (Artl, et al., 2002). The peptide can then produce ROS or 
induce lipid peroxidation, both of which strongly affect lipoprotein stability.   
Conversion of cholesterol to 24S-hydroxycholesterol is believed to be a mechanism by  
which the brain maintains cholesterol homeostasis. Plasma concentrations of 24S-
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hydroxycholesterol are utilized as a biomarker and a diagnostic tool for neurological 
disorders. Neuronal damage is accompanied by destruction of neuronal membranes, which 
causes more cholesterol to be converted into 24S-hydroxycholesterol. In agreement 
significantly higher peripheral concentrations of 24S-hydroxycholesterol were found in 
Alzheimer’s disease and vascular demented patients (Lutjohann at al., 2000). Importantly, the 
latter study showed that the apoE genotype does not contribute significantly to the elevated 
plasma levels of 24S-hydroxycholesterol in Alzheimer’s disease patients (Bretillon, 2000). 
The CSF levels of 24S-hydroxycholesterol appears to be sensitive to changes in the brain 
(possibly because they are not affected by hepatic clearance rates of this oxysterol) and may 
represent better markers both for neurodegenerative diseases and for disturbances in the 
blood brain barrier (Leoni & Caccia, 2011). In early stages of Alzheimer’s disease, there are 
significantly higher CSF concentrations of 24S-hydroxycholesterol suggesting increased 
cholesterol turnover in the CNS during degeneration (Leoni & Caccia, 2011). These levels 
decrease as the disease advances, possibly reflecting the loss of cells expressing cholesterol 
24S-hydroxylase, the enzyme responsible for the conversion of brain cholesterol into 24S-
hydroxycholesterol. In Alzheimer’s disease and mild cognitive impairment, but not in 
normal individuals, the levels of 24S-hydroxycholesterol significantly correlate with CSF 
levels of apoE (Shafaati et al., 2007).  
The elevation of 24S-hydroxycholesterol in CSF is consistent with a significant role for this 
oxysterol as a signaling molecule during neuronal degeneration. It has been shown that 24S-
hydroxycholesterol is able to induce expression of apoE and ABC transporters in astrocytes 
through activation of LXR, and to stimulate cellular cholesterol efflux (Baldan et al., 2009).  
5.3. Diabetes 
Diabetes mellitus is a disease characterized by hyperglycemia and insufficiency or resistance 
to insulin. In general, diabetes is associated with increased generation of free radicals, 
heightened state of oxidative stress, and attenuated antioxidant response. Studies have 
revealed greater levels of TBARS in the plasma of diabetic patients compared to controls 
(Kawamura et al., 1994). Plasma lipoproteins isolated from diabetic rats have been shown to 
be cytotoxic in vitro in cultured cells, suggesting they may have been oxidatively modified in 
vivo (Morel & Chisolm, 1989). Other studies have shown that glucose autoxidation and 
protein glycation can result in the formation of radicals like superoxide anions that promote 
lipoprotein oxidation.   
Hyperglycemia promotes glycation of the protein and lipid components of lipoproteins 
leading to generation of advanced glycation end-products (AGE) (Sun et al., 2009). 
Glycation is the process whereby glucose attaches to the ε-amino group of lysines or the α-
amino group of an N-terminal amino acid in a non-enzymatic manner (Maritim et al., 2003). 
Biochemically, glucose attachment to the protein results in the formation of an unstable 
Schiff base, which then rearranges to an Amadori product. These Amadori products then 
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undergo dehydration reactions and rearrange themselves to finally form AGE, which are 
responsible for many of the irreversible pathological effects seen in diabetes. The receptors 
for AGE (RAGE) are abundantly expressed on vascular endothelial cells, smooth muscle 
cells and macrophages, which are enhanced in atherosclerotic lesions in diabetes. Since Ox-
LDL has AGE epitopes, it binds RAGE on macrophages and enhances macrophage 
proliferation and oxidative stress. 
Like oxidation, glycation of LDL prevents LDLr-mediated cellular uptake of lipoproteins 
and promotes scavenger receptor-mediated uptake.  In vivo, small, dense, which is more 
atherogenic than large buoyant LDL, appears to be preferentially glycated; also, in vitro 
studies suggest that it is more susceptible to glycation (Soran & Durrington, 2011). Diabetic 
individuals display higher plasma concentrations of glycated LDL than non-diabetic 
individuals. 
Type 1 diabetes subjects have lipid disorders (diabetic dyslipidemia), with a pro-atherogenic 
lipid profile: increased concentration of TG and LDL cholesterol, low HDL levels (Verges, 
2009). In addition, they display increased cholesterol-triglyceride ratio within their VLDL, 
increased triglyceride in their LDL and HDL, glycation of apolipoproteins, increased 
oxidation of LDL and an increase in small dense LDL (relatively more atherogenic). HDL 
from Type 1 diabetes subjects is less effective in promoting cholesterol efflux and has 
reduced antioxidant properties.  
Subjects with Type 2 diabetes also have a proatherogenic lipid profile with quantitative and 
qualitative differences in their lipoproteins (Verges, 2005). Typically, they have increased 
triglyceride levels, increased VLDL production and decreased VLDL catabolism, and 
decreased HDL cholesterol levels. They have large VLDL particles that are richer in 
triglyceride, small dense LDL particles, increase in triglyceride content of LDL and HDL, 
Ox- and glycated-LDL, glycation of apolipoproteins and increased susceptibility of LDL to 
oxidation. 
6. Concluding remarks  
In conclusion, this chapter has provided a broad overview of the role of oxidative stress, 
ROS, and lipoprotein oxidation in the pathophysiology of disease states such as 
atherosclerosis, Alzheimer’s disease and diabetes. While Ox-LDL and inflammation seem to 
be bona fide factors in the development of atherosclerosis, the role of dysfunctional HDL in 
these disease states is not known at this point. There are several points of uncertainty 
regarding the in vivo source of ROS and oxidative stress, the physiological behavior of 
oxidized lipoproteins, particularly in Alzheimer’s disease and diabetes, and the line-up of 
antioxidants and autoantibodies in response to the oxidized factors. It is anticipated that the 
next decade will provide more insights into the molecular and mechanistic basis of the effect 
of oxidative damage on lipoprotein in disease states. This would pave the way for new 
therapeutic options for preventing and treating these diseases.     
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